SLC6A4 and Parkinson disease: Moreover, 5-HT transporters in the putamen are significantly increased in PD patients receiving L-DOPA treatment and suffering from LID, as well as in primates developing dyskinesia from L-DOPA treatment (Rylander et al., 2010).